Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Accured (2022 - 2025)

Crinetics Pharmaceuticals has reported Receivables - Accured over the past 4 years, most recently at $7.8 million for Q4 2025.

  • For Q4 2025, Receivables - Accured fell 6.02% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, down 6.02%, while the annual FY2025 figure was $7.8 million, 6.02% down from the prior year.
  • Receivables - Accured for Q4 2025 was $7.8 million at Crinetics Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over five years, Receivables - Accured peaked at $8.4 million in Q2 2025 and troughed at $1.4 million in Q4 2022.
  • A 4-year average of $6.1 million and a median of $7.2 million in 2025 define the central range for Receivables - Accured.
  • Biggest five-year swings in Receivables - Accured: soared 167.74% in 2024 and later dropped 6.02% in 2025.
  • Year by year, Receivables - Accured stood at $1.4 million in 2022, then surged by 121.43% to $3.1 million in 2023, then soared by 167.74% to $8.3 million in 2024, then fell by 6.02% to $7.8 million in 2025.
  • Business Quant data shows Receivables - Accured for CRNX at $7.8 million in Q4 2025, $6.3 million in Q3 2025, and $8.4 million in Q2 2025.